Topics

Clinical Trials About "Peanut genome sequenced with unprecedented accuracy" RSS

19:07 EDT 17th September 2019 | BioPortfolio

We list hundreds of Clinical Trials about "Peanut genome sequenced with unprecedented accuracy" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Peanut genome sequenced with unprecedented accuracy" on BioPortfolio

We have published hundreds of Peanut genome sequenced with unprecedented accuracy news stories on BioPortfolio along with dozens of Peanut genome sequenced with unprecedented accuracy Clinical Trials and PubMed Articles about Peanut genome sequenced with unprecedented accuracy for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Peanut genome sequenced with unprecedented accuracy Companies in our database. You can also find out about relevant Peanut genome sequenced with unprecedented accuracy Drugs and Medications on this site too.

Showing "Peanut genome sequenced with unprecedented accuracy" Clinical Trials 1–25 of 2,100+

Extremely Relevant

Peanut Oral Immunotherapy

This is a study in which increasing amounts of peanut flour are given to the children who are peanut allergic to desensitize them to peanut. The hypothesis is that the peanut allergic patients would benefit from the desensitization by assuring that they will not have life-threatening allergic reactions to contaminating amounts of peanut in other foods and eventually it would cause them to lose their clinical sensitivity to peanut.


Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age

The study aims to assess the safety and efficacy of Viaskin Peanut to induce desensitization to peanut in peanut-allergic children 1 to 3 years of age after a 12-month treatment by EPicutaneous ImmunoTherapy (EPIT).

Boiled Peanut Oral Immunotherapy

Prospective Phase 1 clinical trial providing proof of concept data on boiled peanut oral immunotherapy (OIT) for the treatment of peanut allergy in children. The investigators hypothesize that the proportion of subjects successfully desensitized with boiled peanut OIT is greater than the theoretical placebo rate of 20%.


Early Life Origins of the Food Allergy Epidemic

The purpose of this study is to determine if avoidance of peanut by children with positive allergy testing to peanut in the first 5 years of life increases the likelihood of developing a persistent peanut allergy by age 5 years. To answer this question, the investigators need to determine which children with positive allergy testing to peanut have reactions after eating peanut (allergic to peanut) and which are able to tolerate eating peanut (not allergic). The investiga...

Relevant

Early Peanut Introduction: Translation to Clinical Practice

The recent finding that early introduction of peanut can prevent ~70-90% of peanut allergy is a major step towards prevention of food allergy. However, because that finding was from a clinical trial in a very select population, there are several major questions that must be answered in order to implement these findings into clinical practice without causing more harm than good. These questions include who, if anyone, should be screened prior to early introduction for peanut all...

Peanut Sublingual Immunotherapy

The purpose of this study is to evaluate the safety and immune response to daily sublingual (under the tongue) immunotherapy (SLIT) with peanut extract in adults and children with peanut allergies.

Mucosal Immunotherapy for Peanut Allergy in Young Children

Peanut allergy is known to cause severe anaphylactic reactions.The goal of this proposal is to produce a new treatment that would benefit young subjects who have recently been diagnosed with peanut allergy by lowering the risk of anaphylactic reactions (desensitization), and changing the peanut-specific immune response in subjects who have peanut allergy (tolerance).

Oral Immunotherapy (OIT) for Peanut Allergy

Peanut allergy is known to cause severe anaphylactic reactions.The goal of this proposal is to produce a new treatment that would benefit subjects who have peanut allergy by lowering the risk of anaphylactic reactions (desensitization), and changing the peanut-specific immune response in subjects who have peanut allergy (tolerance).

Double Blind Peanut Sublingual Immunotherapy

The specific aim of this study is to desensitize peanut-allergic subjects with peanut allergen-specific, sublingual immunotherapy (SLIT) by placing drops of peanut protein under the tongue which will be absorbed. The hypothesis is that peanut SLIT will desensitize patients with peanut allergic reactions by changing the subject's immune system to adapt to peanuts.

Peanut Allergy Vaccine Study in Healthy and Peanut-allergic Adults

The purpose of this study is to evaluate the safety and side effects of a study product that contains recombinant modified peanut proteins (EMP-123) in healthy and peanut-allergic participants. This is a first in human study. As of November 2009, this study is no longer recruiting healthy volunteers and will only be recruiting individuals with peanut allergies.

Identification of Anaphylactogenic Antibodies in Peanut Allergy

This project intends the analysis and profiling of specific antibodies against major peanut allergens in peanut allergic individuals and molecular cloning of human antibodies against major peanut allergens.

Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using (CPNA) Peanut OIT Safety Follow-On Study

This is a multi-center, open-label, follow-on study to gather additional information on the safety and tolerability of oral desensitization with CPNA in the subjects who participated in ARC001.

Evaluating the Safety and Efficacy of Fecal Microbiota Transplant in Peanut Allergic Patients

This is a Phase I trial to evaluate the safety and efficacy of fecal microbiota transplantation (FMT) in the treatment of peanut allergy. In this research the investigators would like to learn more about ways to treat peanut allergies. There is currently no known cure for peanut allergy. The primary aim is to assess safety and tolerability of oral FMT in patients with peanut allergy aged 18-40 years.

The Grown Up Peanut Immunotherapy Study

To determine efficacy and safety of peanut oral immunotherapy in adults with peanut allergy.

Understanding How the Immune System Responds to Viruses in Peanut Allergic Children Undergoing Peanut Oral Immunotherapy

The purpose of this study is to find out if there is a way to treat children with peanut allergy to help lower the risk of severe allergic reactions and also cause them to lose their allergy to peanuts and to understand what happens to their immune systems when they have viral infections while on therapy. The approach we will use to treat peanut allergy in this study is a process called desensitization. We think that children with a peanut allergy receiving peanut oral immuno...

A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic Subjects

The study aims to assess the biological potency of the In-House Reference Preparation (IHRP) of peanut allergens extract by a quantitative Skin Prick Test (SPT) method in peanut-allergic subjects.

Take Away Food Allergy; Inducing Tolerance in Children Allergic to Peanut

The purpose of the study is to identify prognostic markers and possible success rate of tolerance induction to peanut allergens in children allergic to peanut.

Safety Study of Viaskin Peanut to Treat Peanut Allergy

This study evaluates the safety of Viaskin Peanut 250 mcg in the treatment of peanut allergy in children from 4 to 11 years of age. Subjects will receive either Viaskin Peanut 250 mcg or a placebo for a period of 6 months, after which all subjects will be receiving the active treatment up to a period of 3 years under active treatment.

Development of an Algorithm to Better Predict Clinical Responsiveness to Peanut

The purpose of this study is to develop a tool to better predict clinical allergy to peanut, so that those who are skin test positive but non allergic will not have to unnecessarily avoid peanut, and those with true allergy can be diagnosed, possibly without oral ingestion challenge, and treated appropriately

Evaluating Peanut Immunotherapy Dissolving Film in Healthy Subjects

Open label, cross-over, local pharmacokinetics study of a sublingual film with peanut extract in healthy adults and children

Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents

To compare the HRQOL of AR101 characterized oral desensitization immunotherapy (CODIT™) in combination with standard of care (peanut avoidance, education) versus standard of care alone in peanut-allergic subjects aged 4 to 17 years.

Salvage Peanut Oral Immunotherapy Study

The purpose of this trial is to provide salvage peanut oral immunotherapy for patients with peanut allergy.

Oral Peanut Immunotherapy

Peanut allergy is one of the most serious food allergies because of its life long persistence, and the potential for severe allergic reactions. Effective oral immunotherapy would benefit patients by reducing the likelihood that they will have life-threatening accidental allergic reactions. This research study is being done to develop an effective oral immunotherapy treatment for patients with peanut allergy.

Peanut Oral Immunotherapy Study of Early Intervention for Desensitization

The purpose of this study is to determine the efficacy and safety of AR101 in peanut‑allergic children aged 1 to < 4 years.

Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball

This study aims to determine if using the peanut ball during the active phase of labor reduces the cesarean delivery rate when compared to normal intrapartum management (no peanut ball) in the obese patient population.


More From BioPortfolio on "Peanut genome sequenced with unprecedented accuracy"

Quick Search